Producer
Repligen Corporation
Repligen Corporation (Waltham MA; Nasdaq: RGEN; ~$700M revenue FY2024) is a bioprocessing technology company that manufactures OPUS pre-packed chromatography columns — stainless-steel-free, single-use chromatography column systems containing Protein A resin (primarily Cytiva MabSelect but also Repligen's own XCell ATF cell retention technology). Repligen's OPUS columns allow biopharmaceutical manufacturers to avoid traditional column packing and qualification steps, reducing process development time and contamination risk. Repligen also manufactures proprietary recombinant Protein A ligands (the biological binding molecule) that it supplies to third-party resin manufacturers — making Repligen a supplier to Cytiva's competitors rather than purely a downstream integrator. Repligen acquired Sweden-based ChromaTech in 2019 to expand its Protein A ligand production. Repligen's Protein A ligand business is a chokepoint within a chokepoint: the company supplies the biological molecule that multiple Protein A resin manufacturers attach to their beads.
1
Inputs supplied
1
Goods downstream
1
Facilities
0
Stories
What they make
1 input Repligen Corporation supplies
Click an input to see every good that depends on it, every country that produces it, and every other company in the supply chain.
Where it shows up
Goods downstream
Essential goods that depend on something Repligen Corporation makes — pick one to see the full supply chain.
What else they do
Business segments
The company's full revenue map — where this supply-chain role fits within their broader business.
Chromatography (OPUS Columns, Resins)
45%Filtration (ATF, hollow fiber)
28%Fluid Management (XCell, tubing)
17%Analytics & Process Development
10%
Intelligence
What's known
Sourced claims about this company's role in supply chains — chokepoints, concentration, incidents, dual-use connections.
Did you know2024
Repligen's Protein A chromatography columns are used to purify therapeutic monoclonal antibodies (Humira, Keytruda, Dupixent — the world's top-selling drugs), but the same Protein A technology purifies research-grade and diagnostic antibodies used in immunoassay tests (COVID lateral flow tests, hospital blood analyzers, research immunoassays). The therapeutic drug supply chain (biopharmaceutical manufacturing) and the diagnostic testing supply chain (point-of-care and laboratory tests) both depend on Repligen's Protein A capacity. During COVID-19, Repligen's OPUS columns were used to produce COVID therapeutic antibodies (Regeneron's REGEN-COV) and COVID vaccines with antibody components — simultaneously being constrained by pandemic diagnostic antibody demand. One Massachusetts bioprocessing company was at the intersection of COVID treatment manufacturing AND COVID testing manufacturing.
Repligen Corporation ↗Origin2023
Repligen Corporation began in the 1980s as a biotechnology research company working on Protein A — a surface protein from the bacterium Staphylococcus aureus that happens to bind selectively to human antibodies. Repligen licensed Protein A for diagnostic applications, then recognized that biopharmaceutical companies were paying enormous amounts to purify therapeutic monoclonal antibodies using Protein A chromatography. Repligen pivoted to become the supplier of Protein A ligands and chromatography columns for the growing mAb manufacturing industry, becoming a critical infrastructure provider for the world's most profitable drug class without being a drug company itself.
Repligen Corporation ↗